Fresenius Medical Care ( (FMS) ) has provided an update.
On February 25, 2025, Fresenius Medical Care announced its fourth quarter and full year 2024 results, reporting an 18% growth in operating income. The company successfully executed its strategic turnaround plan, achieving significant savings through the FME25 program and raising its savings target to EUR 750 million for 2025. The positive momentum in Care Delivery and Care Enablement segments contributed to the company’s financial performance, with plans to increase the dividend by 21% and reduce net financial leverage.
More about Fresenius Medical Care
Fresenius Medical Care is a leading global provider of products and services for individuals with renal diseases. The company focuses on delivering care through its Care Enablement and Care Delivery segments, aiming to optimize its legacy portfolio and improve operational efficiency.
YTD Price Performance: 5.24%
Average Trading Volume: 253,501
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13.7B
See more data about FMS stock on TipRanks’ Stock Analysis page.